TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) Director Gary Gordon bought 10,000 shares of the company's stock in a transaction that occurred on Tuesday, November 17th. The shares were purchased at an average cost of $2.20 per share, for a total transaction of $22,000.00. Following the acquisition, the director owned 82,510 shares of the company's stock, valued at $181,522. This represents a 13.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
TriSalus Life Sciences Stock Down 11.4%
NASDAQ:TLSI traded down $0.28 during trading hours on Thursday, hitting $2.17. 364,646 shares of the company's stock traded hands, compared to its average volume of 302,213. The stock's fifty day moving average price is $3.90 and its two-hundred day moving average price is $4.26. The firm has a market cap of $133.62 million, a P/E ratio of -4.43 and a beta of 0.50. The company has a debt-to-equity ratio of 47.60, a quick ratio of 3.86 and a current ratio of 4.22. TriSalus Life Sciences, Inc. has a twelve month low of $2.16 and a twelve month high of $7.95.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The company had revenue of $12.88 million during the quarter, compared to analysts' expectations of $14.02 million. On average, research analysts expect that TriSalus Life Sciences, Inc. will post -0.62 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the stock. Wall Street Zen downgraded shares of TriSalus Life Sciences from a "hold" rating to a "sell" rating in a research note on Saturday, November 7th. Citigroup restated a "buy" rating on shares of TriSalus Life Sciences in a research report on Tuesday, November 10th. Canaccord Genuity Group lowered their target price on shares of TriSalus Life Sciences from $7.00 to $4.00 and set a "buy" rating on the stock in a report on Tuesday, November 10th. Zacks Research upgraded TriSalus Life Sciences to a "hold" rating in a research note on Thursday, September 10th. Finally, Guggenheim set a $12.00 price objective on TriSalus Life Sciences in a research report on Wednesday, September 23rd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $9.20.
View Our Latest Analysis on TLSI
Institutional Trading of TriSalus Life Sciences
A number of institutional investors have recently modified their holdings of TLSI. First Light Asset Management LLC acquired a new position in shares of TriSalus Life Sciences during the 1st quarter worth approximately $20,267,000. BlackRock Inc. acquired a new position in TriSalus Life Sciences in the 2nd quarter valued at about $12,099,000. Nantahala Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the second quarter worth approximately $4,550,000. White Pine Capital LLC acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth $2,143,000. Finally, State Street Corp boosted its holdings in TriSalus Life Sciences by 86.3% in the 2nd quarter. State Street Corp now owns 610,963 shares of the company's stock valued at $2,780,000 after purchasing an additional 282,943 shares during the period. 2.58% of the stock is currently owned by institutional investors.
TriSalus Life Sciences Company Profile
(
Get Free Report)
TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company's TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.